No mutation in the entire coding region of the α-synuclein gene in pathologically confirmed cases of multiple system atrophy

doi:10.1016/S0304-3940(99)00475-9

Neuroscience Letters

Volume 270, Issue 2, 30 July 1999, Pages 110-112

https://doi.org/10.1016/S0304-3940(99)00475-9 Get rights and content

Abstract

To determine whether mutations in the coding region of the α-synuclein gene are relevant in cases of multiple system atrophy (MSA), detailed nucleotide sequence analysis of the α-synuclein gene was performed using total RNA obtained from autopsied brain specimens of 11 pathologically confirmed cases of MSA. The brain specimens used in this study contained both gray and white matter, which were dissected from the frontal, temporal or occipital lobe. No nucleotide alterations were found in the entire coding region of the α-synuclein gene in any of the cases. While mutations in the regulatory or intronic regions of the gene were not ruled out, our results suggest that mutations in the coding region of the α-synuclein gene are unlikely to contribute to the pathogenesis of MSA.

References (16)

O.M.A. El-Agnaf et al.
Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease
FEBS Lett.
(1998)
M.I. Papp et al.
Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy–Drager syndrome)
J. Neurol. Sci.
(1989)
K. Wakabayashi et al.
NACP, a presynaptic protein, immunoreactivitiy in Lewy bodies in Parkinson's disease
Neurosci. Lett.
(1997)
K. Wakabayashi et al.
α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
Neurosci. Lett.
(1998)
Consensus Committee of the American Autonomic Society and the American Academy of Neurology, Consensus statement on the...
K.A. Conway et al.
Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease
Nat. Med.
(1998)
H. Kobayashi et al.
Stability of messenger RNA in postmortem human brains and construction of human brain cDNA libraries
J. Mol. Neurosci.
(1990)
R. Krüger et al.
Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease
Nat. Genet.
(1998)

There are more references available in the full text version of this article.

Cited by (61)

Glia and alpha-synuclein in neurodegeneration: A complex interaction
2016, Neurobiology of Disease
Citation Excerpt :
Polymorphisms within the SNCA gene might induce the development of MSA (Al-Chalabi et al., 2009; Scholz et al., 2009). However, in different studies and in a genome-wide association study the polymorphisms in the SNCA gene in MSA could not be confirmed (Ozawa et al., 1999; Yun et al., 2010; Ahmed et al., 2012). Impairment of COQ2 and therefore inducing a functional impairment of the mitochondrial respiratory chain and enhanced vulnerability to oxidative stress were described in Japanese patients recently (Multiple-System Atrophy Research, C, 2013), yet no such correlation between loss-of-function of COQ2 variants and increased risk of MSA in Europeans and Koreans was found (Jeon et al., 2014; Schottlaender et al., 2014; Sharma et al., 2014).
α-Synucleinopathies (ASP) comprise adult-onset, progressive neurodegenerative disorders such as Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) that are characterized by α-synuclein (AS) aggregates in neurons or glia. PD and DLB feature neuronal AS-positive inclusions termed Lewy bodies (LB) whereas glial cytoplasmic inclusions (GCIs, Papp–Lantos bodies) are recognized as the defining hallmark of MSA. Furthermore, AS-positive cytoplasmic aggregates may also be seen in astroglial cells of PD/DLB and MSA brains. The glial AS-inclusions appear to trigger reduced trophic support resulting in neuronal loss. Moreover, microgliosis and astrogliosis can be found throughout the neurodegenerative brain and both are key players in the initiation and progression of ASP. In this review, we will highlight AS-dependent alterations of glial function and their impact on neuronal vulnerability thereby providing a detailed summary on the multifaceted role of glia in ASP.
Animal Models of Multiple-System Atrophy
2015, Movement Disorders: Genetics and Models: Second Edition
Multiple-system atrophy (MSA) is a rapidly progressive and fatal neurodegenerative disorder characterized by glial α-synuclein inclusion pathology. The clinical presentation includes autonomic failure, levodopa-unresponsive parkinsonism and cerebellar symptoms in variable combinations. Thus far, there are no established disease-modifying therapies available, and key molecular events underlying disease pathogenesis and spread remain largely elusive. However, in recent years, several animal models mimicking MSA-related pathological and clinical features have been developed that exploit both toxic and transgenic approaches. Nevertheless, additional experimental studies are urgently required to unravel the etiopathogenesis of MSA and to identify targets for interventional therapies. In this chapter we provide a comprehensive overview of the clinical presentation, pathological and pathophysiological underpinnings, as well as currently available animal models.
Genomic aspects of sporadic neurodegenerative diseases
2014, Biochemical and Biophysical Research Communications
Sporadic neurodegenerative diseases are complex in nature, that is, they involve multiple genetic and environmental factors that may play roles at the molecular level. In contrast to diseases with Mendelian inheritance, the genomic signatures of common sporadic forms of neurodegenerative diseases largely remain unknown. Over the past decade, genome-wide association studies employing common single-nucleotide polymorphisms have been intensively conducted, in which the theoretical framework is based on the “common disease–common variants” hypothesis. Another paradigm is a sequence-based association study under the “common disease–multiple rare variants” hypothesis. Because current next-generation sequencing technologies enable us to obtain virtually all the variants in human genome irrespective of allele frequencies, it is anticipated that sequence-based association studies will become the mainstream approach. In this review, we present brief overviews of molecular genetic approaches to elucidate the molecular bases of sporadic forms of neurodegenerative diseases, including Alzheimer disease, Parkinson disease, and multiple system atrophy as examples.
Genetic players in multiple system atrophy: Unfolding the nature of the beast
2011, Neurobiology of Aging
Citation Excerpt :
One German family with probable MSA affecting 2 members in 2 successive generations was described (Wullner et al., 2004). Genetic testing excluded spinocerebellar ataxia (SCA) types 1–3, 6, 7, and 17 as well as mutations in the α-synuclein gene (Ozawa et al., 1999; Wullner et al., 2004). One affected patient died subsequently and the diagnosis was confirmed according to standard neuropathological criteria (Trojanowski and Revesz, 2007; Wullner et al., 2009).
Multiple system atrophy (MSA) is a fatal oligodendrogliopathy characterized by prominent α-synuclein inclusions resulting in a neuronal multisystem degeneration. Until recently MSA was widely conceived as a nongenetic disorder. However, during the last years a few postmortem verified Mendelian pedigrees have been reported consistent with monogenic disease in rare cases of MSA. Further, within the last 2 decades several genes have been associated with an increased risk of MSA, first and foremost the SNCA gene coding for α-synuclein. Moreover, genes involved in oxidative stress, mitochondrial dysfunction, inflammatory processes, as well as parkinsonism- and ataxia-related genes have been implicated as susceptibility factors. In this review, we discuss the emerging evidence in favor of genetic players in MSA.
Etiology, Pathology, and Pathogenesis
2010, Blue Books of Neurology
Citation Excerpt :
Initial screening studies for candidate genes revealed no risk factors, however.21-23 While it has been shown that α-synuclein plays a role in the pathogenesis of some types of familial (but not sporadic) PD,24 no mutations in the entire coding region of the α-synuclein gene have been found in MSA.25 However, α-synuclein gene variants have been related to an increased risk of MSA in a multi-centre whole genomic association study recently.26
This chapter reviews the available evidence on the etiopathogenesis and pathology of multiple system atrophy (MSA). MSA is a neurodegenerative disease of unknown etiology that manifests clinically with autonomic failure, parkinsonism, cerebellar ataxia, and pyramidal signs in various combinations. The finding of polymorphisms in various proinflammatory pathways is a promising step in elucidating the pathogenesis of MSA. There is significant overlap in the clinical features between the fragile X–associated tremor/ataxia syndrome (FXTAS) and atypical parkinsonism—in particular, MSA associated with cerebellar ataxia (MSA-C). Polymorphisms associated with an elevated risk for MSA include interleukin (IL)-1A, IL-1β, IL-8, intercellular adhesion molecule-1, tumor necrosis factor-1031C,38, and α₁-antichymotrypsin. Diffuse neuronal cytoplasmic α-synuclein immunoreactivity is often referred to as “preinclusions” and may reflect incipient inclusion or Lewy body-like formation enhanced in sympathetic ganglia in MSA patients. Although MSA is now widely accepted as a single multisystem disease, there is evidence of clinicopathological heterogeneity. Autonomic failure in MSA is caused by dysfunction of (1) central and preganglionic efferent autonomic activity, (2) neuronal networks in the brainstem that control cardiovascular and respiratory function, and (3) the neuroendocrine component of the autonomic regulation via the hypothalamopituitary axis. The correlation of subregional glial cytoplasmic inclusion (GCI) density and neuronal loss suggests that α-synuclein aggregation is tightly linked to selective neurodegeneration in MSA.
Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials
2024, Journal of Neurology

View all citing articles on Scopus

View full text

No mutation in the entire coding region of the α-synuclein gene in pathologically confirmed cases of multiple system atrophy

Abstract

FEBS Lett.

J. Neurol. Sci.

Neurosci. Lett.

Neurosci. Lett.

Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease

Nat. Med.

Stability of messenger RNA in postmortem human brains and construction of human brain cDNA libraries

J. Mol. Neurosci.

Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease

Nat. Genet.